Bristol-Myers Squibb Company is rated a Buy with solid rebound and robust free cash flow margins. Learn more about BMY stock ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Several of the largest US and European drugmakers struck agreements with President Donald Trump ...

Johnson & Johnson and Bristol Myers Squibb Co. are urging the US Supreme Court to review a Biden-era program that allows Medicare to negotiate drug prices with pharmaceutical giants.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, ...

Bristol Myers Squibb sees India as a major growth driver. The company is investing heavily in AI to speed up drug launches and improve doctor engagement. New medicines for heart conditions and cancer ...

Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...

Furthermore, the firm sees favorable risk/reward as Bristol-Myers Squibb Company (NYSE:BMY) approaches 2026 filled with ...

Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative breast cancer.

Bristol Myers Squibb and Accenture launch AI content hub 'Mosaic' in Mumbai, enhancing digital capabilities with a $130 ...

Cytokinetics Inc. won US approval for a drug to treat a deadly heart condition, posing a potential threat to sales of a ...